Prognosis
Goldman Says Moderna Vaccine Filing May Be Sooner Than Expected
Healthcare workers register people at a Covid-19 testing site in a parking garage in St. Petersburg, Florida on July 14.
Photographer: Eve Edelheit/BloombergThis article is for subscribers only.
Moderna Inc. could file interim results on its Covid-19 vaccine candidate with U.S. regulators sooner than many investors are expecting, Goldman Sachs Group Inc. said.
The biotech is slated to start a 30,000-patient trial July 27 and the chances of an early filing on the results is underappreciated, analysts led by Salveen Richter said. The likelihood of getting a successful vaccine in 2020 are enhanced further by four other vaccine programs slated to enter into the final research phase of testing sometime this summer, according to Goldman.